What am I missing here? The number of reported injuries arising from use of Pradaxa continues to grow at an unparalleled pace and yet financial and pharmaceutical analysts celebrate Boehringer Ingelheim as profits on its blockbuster drug, Pradaxa, continue to surge.
In the last three months of 2011, the FDA collected 3,000 reports of adverse events for Pradaxa, earning Boehringer Ingelheim’s blockbuster drug the fifth spot on the Top Ten Drugs with the Most Adverse Reports List for 2011 Q4. Of those 3,000 reported adverse events, 459 deaths, 69 disabilities, and 1,331 hospitalizations resulted – making it the drug with the most associated deaths for the quarter.
Meanwhile, Boehringer Ingelheim is enjoying an increase in after-tax profits by 66% and sales increases of 5% as the financial and pharmaceutical journals attribute a large percentage of the increased sales to Pradaxa which officially graduated to “blockbuster” status as a result (blockbuster status is defined as generating annual sales of $1 billion or more).
Where is the disconnect? Why is this drug selling at such a high rate given all the negative press out there?
Source: AdverseEvents Monitor